Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Fever
Interventions: text message surveillance for fever; Other
Lead sponsor: Columbia University; Other
Eligibility: 24 Months to 59 Months
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Respiratory Tract Infection, Bronchitis, Pneumonia
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 3
States / cities: St Louis, Missouri • Lake Success, New York • Temple, Texas

Conditions: Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever
Interventions: Not listed
Lead sponsor: Cellex, Inc.; Industry
Eligibility: Not listed
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland

Conditions: Influenza
Interventions: A/Vietnam/1203/04, A/Indonesia/05/05; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Decatur, Georgia • Rochester, Minnesota • St Louis, Missouri + 1 more

Conditions: Influenza
Interventions: Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza Vaccine
Interventions: Sing2016 M2SR H3N2 influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • Lenexa, Kansas

Conditions: Influenza
Interventions: Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV); Biological
Lead sponsor: Novartis; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 3,604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more

Conditions: Healthy Volunteer
Interventions: Ad4-H5-Vtn; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Influenza, Influenza-like Illness
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more

Conditions: Influenza, Respiratory Virus, Coronavirus
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel; Diagnostic Test
Lead sponsor: Thermo Fisher Scientific, Inc; Industry
Eligibility: Not listed
Enrollment: 1,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: San Diego, California • Lake City, Florida • Miami, Florida + 13 more

Conditions: Influenza
Interventions: Standard IIV4, Recombinant, Cell-culture; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
Interventions: LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: 2 Years and older
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cullman, Alabama

Conditions: MELAS Syndrome
Interventions: Fluzone®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID-19 Respiratory Infection, Influenza
Interventions: RD-X19, RD-X19 Sham; Device
Lead sponsor: David Moss; Federal
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 9 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Influenza
Interventions: Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 9 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Rochester, New York

Conditions: Reminder Systems, Influenza Vaccines
Interventions: Reminders; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 17 Years
Enrollment: 25,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza, Human
Interventions: PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more

Conditions: Influenza
Interventions: Instramuscular vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 14
States / cities: Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more

Conditions: Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients

Clinical Evaluation of QFlu Combo Test

H5N1 Priming and Boosting Strategies

Bone Marrow and Peripheral Blood Immune Responses Study

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

H5N1 Mix and Match With AS03

Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Project STARFISH - PRJ0002679

Randomized Influenza Vaccine Evaluation of Immune Response

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Study of the Immune Response After Vaccination in Multiple Myeloma Patients